Browse > Article
http://dx.doi.org/10.4014/jmb.1509.09061

Immune Modulation of Recombinant OmpA against Brucella abortus 544 Infection in Mice  

Simborio, Hannah Leah Tadeja (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Reyes, Alisha Wehdnesday Bernardo (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Hop, Huynh Tan (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Arayan, Lauren Togonon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Min, Wongi (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Lee, Hu Jang (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Lee, Jin Ju (Animal and Plant Quarantine Agency)
Chang, Hong Hee (Institute of Agriculture and Life Science, Gyeongsang National University)
Kim, Suk (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Publication Information
Journal of Microbiology and Biotechnology / v.26, no.3, 2016 , pp. 603-609 More about this Journal
Abstract
Brucellosis affects a wide range of host species, including humans and many livestock animals. Chronic infections of the disease make antibiotic treatment costly, and the current vaccine used in livestock has not been approved for human use. This study investigated the possible use of the Brucella abortus outer membrane protein A (OmpA) as a candidate subunit vaccine in an infected mouse model. The ompA gene was cloned and overexpressed, and the recombinant OmpA (rOmpA) protein fused to maltose binding protein (MBP) was purified in Escherichia coli. Immunogenicity was verified through western blotting, and mice were immunized and challenged to evaluate its protective effect. Mice treated with rOmpA exhibited induced humoral and host cell-mediated responses, with a significant increase in immunoglobulin G (IgG1 and IgG2a) and cytokine levels, especially TNF-α and IL-12, compared with the control groups treated with either MBP or PBS. In conclusion, rOmpA should be highly considered as a future subunit vaccine for brucellosis, and further studies regarding rOmpA and its protective ability are suggested.
Keywords
Brucella abortus; outer membrane protein A; recombinant; vaccine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Acha PN, Szyfres B. 2003. Brucellosis, pp. 40-67. In: Zoonoses and Communicable Disease Common to Man and Animals. Vol. 1. Bacterioses and Mycoses. Pan American Health Organization, Washington, DC.
2 Akova M, Uzun O, Akalin HE, Haryan M, Unal S, Gur D. 1993. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob. Agents Chemother. 37: 1831-1834.   DOI
3 Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, et al. 2001. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvants. Infect. Immun. 69: 4816-4822.   DOI
4 Athanassakis I, Iconomidou B. 1996. Cytokine production in the serum and spleen of mice from day 6 to 14 of gestation: cytokines/placenta/spleen/serum. Dev. Immunol. 4: 247-255.   DOI
5 Aygen B, Doganay M, Sumerkan B, Yildiz O, Kayabas U. 2002. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Méd. Mal. Infect. 32: 485-493.   DOI
6 Barrionuevo P, Cassataro J, Delpino MV, Zwerdling A, Pasquevich KA, Garcia Samartino C, et al. 2008. Brucella abortus inhibits major histocompatibility complex III expression and antigen processing through interleukin-6 secretion via Toll-like receptor 2. Infect. Immun. 76: 250-262.   DOI
7 Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. 2007. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 25: 6721-6729.   DOI
8 Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. 2005. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide against Brucella melitensis infection. Infect. Immun. 73: 8079-8088.   DOI
9 Corbel MJ. 1997. Recent advances in brucellosis. J. Med. Microbiol. 46: 101-103.   DOI
10 Dabo SM, Confer A, Montelongo M, York P, Wyckoff JH. 2008. Vaccination with Pasteurella multocida recombinant OmpA induces strong but non-protective and deleterious Th2-type immune response in mice. Vaccine 26: 4345-4351.   DOI
11 Eskra L, Canavessi A, Carey M, Splitter G. 2001. Brucella abortus genes identified following constitutive growth and macrophage infection. Infect. Immun. 69: 7736-7742.   DOI
12 Jimenez de Bagues MP, Barberan M, Marin CM, Blasco JM. 1995. The Brucella abortus RB51 vaccine does not confer protection against Brucella ovis in rams. Vaccine 13: 301-304.   DOI
13 Ficht TA, McDonagh MMK, Gamboa AMA, Ficht ACR. 2009. Brucellosis: the case for live, attenuated vaccines. Vaccine 27: 40-43.   DOI
14 Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding B. 2003. Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J. Immun. 171: 1441-1446.   DOI
15 Jeannin P, Renno T, Goetsch L, Miconnet I, Aubry JP, Delneste Y, et al. 2000. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 1: 502-509.   DOI
16 Lim JJ, Kim DH, Lee JJ, Kim DG, Min W, Lee HJ, et al. 2012. Evaluation of recombinant 28 kDa outer membrane protein of Brucella abortus for the clinical diagnosis of bovine brucellosis in Korea. J. Vet. Med. Sci. 74: 687-691.   DOI
17 Kaushik P, Singh DK, Kumar SV, Tiwari AK, Shukla G, Dayal S, Chaudhuri P. 2010. Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet. Res. Commun. 34: 119-132.   DOI
18 Leclerq S, Harms JS, Rosinha GMS, Azevedo V, Oliveira SC. 2002. Induction of a Th1-type of immune respose but not protective immunity by intramuscular DNA immunization with Brucella abortus GroEL heat-shock gene. J. Med. Microbiol. 51: 20-26.   DOI
19 Lee JJ, Lim JJ, Kim DG, Simborio HL, Kim DH, Reyes AWR, et al. 2014. Characterization of culture supernatant proteins from Brucella abortus and its protection effects against murine brucellosis. Comp. Immunol. Microbiol. Infect. Dis. 37: 221-228.   DOI
20 Lin J, Huang S, Zhang Q. 2002. Outer membrane proteins: key players for bacterial adaptation in host niches. Microbes Infect. 4: 325-331.   DOI
21 Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, et al. 2013. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine 31: 313-318.   DOI
22 Lindler LE, Hadfield TL, Tall BD, Snelling NJ, Rubin FA, van de Verg LL. 1996. Cloning of Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis. Infect. Immun. 64: 2490-2499.
23 Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, Dungo B, Amanfu W. 2007. Veterinary vaccine and their use in developing countries. Rev. Sci. Tech. 26: 179-201.   DOI
24 Nicoletti PL. 2002. A short history of brucellosis. Vet. Microbiol. 90: 5-9.   DOI
25 Macedo GC, Magnani DM, Carvalho NB, Bruna-Romero O, Gazzinelli RT, Oliveira SC. 2008. Central role of MyD88-dependent dendritic cell maturation and proinflammatory cytokine production to control Brucella abortus infection. J. Immunol. 180: 1080-1087.   DOI
26 Makidon PE, Knowlton J, Groom JV, Blanco LP, LiPuma JJ, Bielinska AU, Baker JR. 2010. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med. Microbiol. Immunol. 199: 81-92.   DOI
27 Moriyón I, Lopez-Goni I. 1998. Structure and properties of the outer membranes of Brucella abortus and Brucella melitensis. Int. Microbiol. 1: 19-26.
28 Pasquevich KA, Estein SM, Samartino CG, Zwerdling A, Coria LM, Barrionuevo P, Cassataro J. 2009. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect. Immun. 77: 436-445.   DOI
29 Oliveira SC, Splitter GA. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14: 959-962.   DOI
30 Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, et al. 2003. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect. Immun. 71: 4857-4861.   DOI
31 Pore D, Mahata N, Pal A, Chakrabarti MK. 2011. Outer membrane protein (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS One 6: e22663.   DOI
32 Ragan VE. 2002. The animal and plant health inspection service (APHIS) brucellosis eradication program in the United States. Vet. Microbiol. 90: 11-18.   DOI
33 Schurig GG, Sriranganathan D, Corbel MG. 2002. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90: 479-496.   DOI
34 Soulas C, Baussant T, Aubry JP, Delneste Y, Barillat N, Caron G, et al. 2000. Outer membrane protein A (OmpA) binds to and activates human macrophages. J. Immun. 165: 2335-2340.   DOI
35 Zhan Y, Liu Z, Cheers C. 1996. Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisims. Infect. Immun. 64: 2782-2786.